
Olmesafe-HT20 mg+12.5
Orion Pharma Ltd.
Established / FDA-Approved Use Olmesartan Medoxomil + Hydrochlorothiazide is indicated for the treatment of hypertension (high blood pressure) and more.
Olmesartan Medoxomil + Hydrochlorothiazide is indicated for the treatment of hypertension (high blood pressure), either asinitial therapy in patients likely to need multiple drugs to achieve their blood pressure goal, or assubstitution/add-on therapy in patients whose blood pressure is not adequately controlled on olmesartanmedoxomil or hydrochlorothiazide monotherapy alone.
Major hypertension guidelines (e.g. ACC/AHA, ESC/ESH) support combination angiotensin II receptor blocker(ARB) plus thiazide diuretic therapy such as Olmesartan Medoxomil + Hydrochlorothiazide for patients who do not reach target bloodpressure on a single agent, or who present with stage 2 hypertension requiring combination therapy from theoutset.
Olmesartan Medoxomil + Hydrochlorothiazide lowers blood pressure but has not been shown to reduce cardiovascular morbidity andmortality as a fixed-dose starting therapy; it is not intended as initial single-pill therapy for mild,uncomplicated hypertension where monotherapy is appropriate, and it is not indicated for use in pregnancy.
| Step | Dose |
|---|---|
| Usual starting dose | Olmesartan medoxomil 20 mg / Hydrochlorothiazide 12.5 mg once daily |
| Titration | If blood pressure is not controlled after 2–4 weeks, the dose may be increased to20 mg/25 mg or 40 mg/12.5 mg, and further to the maximum of 40 mg/25 mg once daily |
| Maximum dose | Olmesartan medoxomil 40 mg / Hydrochlorothiazide 25 mg once daily |
Use with caution in mild-to-moderate renal impairment with periodic monitoring of renal function andelectrolytes; thiazide diuretics are generally not effective and Olmesartan Medoxomil + Hydrochlorothiazide is not recommended inpatients with severe renal impairment (creatinine clearance below approximately 30 mL/min).
No dedicated dose adjustment has been established; use cautiously in hepatic impairment as thiazides canprecipitate hepatic coma in susceptible patients (see Precautions).
Safety and efficacy of Olmesartan Medoxomil + Hydrochlorothiazide have not been established in pediatric patients (seePediatric Use).
The following side effects have been reported with Olmesartan Medoxomil + Hydrochlorothiazide:
| System | Effects |
|---|---|
| General | Headache, dizziness, fatigue, back pain, chest pain |
| Gastrointestinal | Nausea, abdominal discomfort, diarrhea |
| Metabolic | Hyperuricemia, hyperglycemia, elevated cholesterol/triglycerides |
| Infections | Upper respiratory tract infection, urinary tract infection |
| Musculoskeletal | Arthralgia, muscle cramps |
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.